ReviewFrontiers in pharmacology2026
Modulation of the PI3K/Akt signaling pathway by steroidal saponins: therapeutic implications in cancer.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway is considered essential for cancer progression and the regulation of cellular processes, including proliferation, survival, metastasis, and angiogenesis. Conventional therapies using targeted agents such as alpelisib and everolimus have limited the effectiveness of inhibitors in exploiting effective resistance mechanisms. Steroidal saponins (SSs) are a diverse group of natural compounds recognized as anticancer agents that target multiple cells and pathways. Purpose: To synthesize current evidence on how SSs modulate the PI3K/Akt pathway to produce anticancer effects and to outline translational opportunities and limitations. Methods: We conducted a review of preclinical and translational studies indexed in PubMed/Scopus/Google Scholar up to August 2025. Studies were included if they reported mechanistic or functional modulation of the PI3K/Akt/mTOR axis ( Results and Discussion: This review highlights the potential of SSs to target the PI3K/Akt pathway and combat cancer progression, and addresses the limitations of conventional therapies in overcoming therapeutic resistance. SSs, as small-molecule phytochemicals, exert anticancer effects through the induction of apoptosis, inhibition of metastasis and angiogenesis, alteration of the tumor microenvironment to therapeutic advantage, promotion of the immune response, and other mechanisms that reverse multidrug resistance by modulating the PI3K/Akt pathway. Conclusion: The combination of SSs with chemotherapeutic agents, given emerging preclinical evidence of small-molecule efficacy, supports the development of new anticancer therapies. However, the development of SSs for clinical use remains limited due to their low bioavailability, systemic toxicity, and lack of target specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.